Boehringer Ingelheim Backs Ecuador’s Rabies Elimination Push
Event summary
- Ecuador aims to eliminate dog-mediated rabies by 2030, following Mexico as the second Latin American country to do so.
- Boehringer Ingelheim’s Stop Rabies program supports the Ecuador Free of Rabies project through vaccination, education, and surveillance efforts.
- The project targets 80% vaccination coverage of the dog population and aims to educate 4 million children by 2030.
- No dog-to-human rabies transmission cases have been reported in Ecuador since 2006.
- Boehringer Ingelheim’s Stop Rabies program, launched in 2022, aligns with its Sustainable Development for Generations strategy.
The big picture
Boehringer Ingelheim’s support for Ecuador’s rabies elimination aligns with global efforts to address zoonotic diseases, reflecting a broader trend in public-private partnerships targeting health security. The initiative underscores the growing recognition of the interconnectedness of human, animal, and environmental health, particularly in regions with high rabies prevalence. The success of this project could set a precedent for similar collaborations in other parts of the world.
What we're watching
- Execution Risk
- Whether Ecuador can sustain the pace of vaccination and surveillance efforts to meet the 2030 elimination target.
- Regulatory Alignment
- How PAHO’s guidelines will influence other Latin American countries’ rabies elimination strategies.
- Strategic Impact
- The extent to which Boehringer Ingelheim’s Stop Rabies program can replicate this model in other high-risk regions.
Related topics